Your browser doesn't support javascript.
loading
Efficacy of the World Health Organization analgesic ladder in the paclitaxel-induced pain syndrome in rats.
Pinheiro, Kelly de Vargas; Brusco, Indiara; Hausen, Bruna Dos Santos; Moresco, Rafael Noal; Rigo, Flávia K; Oliveira, Sara Marchesan; Ferreira, Juliano.
  • Pinheiro KV; Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria, RS, Brazil.
  • Brusco I; Graduate Program in Biological Sciences: Biochemistry Toxicology, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria, Camobi, Santa Maria, 97105-900, RS, Brazil.
  • Hausen BDS; Graduate Program in Pharmaceutics Sciences, Federal University of Santa Maria, Santa Maria, RS, Brazil.
  • Moresco RN; Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria, RS, Brazil.
  • Rigo FK; Graduate Program in Pharmaceutics Sciences, Federal University of Santa Maria, Santa Maria, RS, Brazil.
  • Oliveira SM; Graduate Program in Health Sciences, University of Extrem South Catarina, Criciuma, SC, Brazil.
  • Ferreira J; Graduate Program in Biological Sciences: Biochemistry Toxicology, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria, Camobi, Santa Maria, 97105-900, RS, Brazil. saramarchesan@hotmail.com.
Inflammopharmacology ; 28(6): 1677-1689, 2020 Dec.
Article en En | MEDLINE | ID: mdl-32266637
ABSTRACT
Paclitaxel use in cancer treatment is limited by a painful syndrome that has no effective treatment. Despite new therapies, drugs of the World Health Organization (WHO) analgesic ladder remain a useful therapeutic tool for cancer pain relief. Since cancer pain is caused by both tumor and chemotherapy, we assessed the efficacy of drugs from the WHO analgesic ladder for cancer pain relief in a paclitaxel-induced pain syndrome (P-IPS) model. P-IPS was induced in rats by one or four injections of paclitaxel on alternate days. The acute and chronic phases were assessed 24 h and 15 days after the first paclitaxel injection, respectively. The mechanical allodynia was evaluated after (step 1 of the ladder) paracetamol, (step 2) codeine alone or plus paracetamol and (step 3) morphine treatment in the acute or chronic phase of P-IPS. Paracetamol, codeine and morphine were equally efficacious in reducing the acute phase of the P-IPS. Codeine plus paracetamol had similar efficacy and potency when administered together in the acute phase of the P-IPS, but produced a longer-lasting effect than when separately managed. Moreover, paracetamol, codeine and morphine partially reduced the chronic phase of P-IPS, losing their efficacy and, in the case of codeine, potency when compared to the acute phase. However, paracetamol plus codeine increased the potency and efficacy of the codeine when compared to codeine administered alone in the chronic phase of P-IPS, producing a long-lasting anti-allodynic effect. Together, analgesics of WHO analgesic ladder reduce both acute and chronic phases of P-IPS, with codeine plus paracetamol presenting more potent, efficacious and long-lasting effect. Thus, in addition to tumor pain, drugs of WHO analgesics ladder could also be useful to treat P-IPS.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dolor / Paclitaxel / Analgésicos Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dolor / Paclitaxel / Analgésicos Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article